PreciseDx raises $10.75M in funding

LabPulse.com staff writers
Jan 11, 2022
2021 06 02 20 19 9323 Business Computer Investigation Magnifying Glass 400

Cancer risk stratification company PreciseDx announced that it has raised $10.75 million in series A funding. The funds will be used to support the ongoing development and commercialization of its (artificial intelligence) AI-powered risk stratification platform.

Also, the company announced the appointment of Wayne Brinster to CEO, which was effective September 2021. Brinster has more than 30 years of experience and held management positions at MedTest, Wheaton Industries/DWK, Synthon Pharmaceuticals, and Becton Dickinson.

Latest in Cancer
Breast Cancer2 Social
Myriad Genetics enters 5 MRD test research collaborations
October 9, 2024
Blood Test Samples Lab Social
Dana-Farber researchers develop CRISPR-based tests for leukemia
October 10, 2024
Body composition in patients treated with Ozempic
Sponsored
Body composition in patients treated with Ozempic
September 20, 2024
Colorectal Cancer Social (1)
Geneoscopy adds N.Y. state lab permit for wider ColoSense testing
October 1, 2024
Related Stories
Financials Growth Revenue Business Social
Financing
PreciseDx raises $20.7M in series B funding
Breast Cancer 3 D Social
Regulatory Approval
New York State Department of Health approves PreciseDx breast cancer LDT
Pathology Digital Workstation Microscope Social
Artificial Intelligence
PreciseDx, Dordrecht Albert Schweitzer Hospital to evaluate cancer risk stratification platform
Body composition in patients treated with Ozempic
Sponsor Content
Body composition in patients treated with Ozempic
More in Cancer
Myriad Genetics enters 5 MRD test research collaborations
By LabPulse.com staff writers
Precision medicine company Myriad Genetics has entered into five ongoing research collaborations aimed at studying the use of molecular residual disease (MRD) testing in breast cancer using Myriad's Precise MRD test.
October 9, 2024
Breast Cancer2 Social
Dana-Farber researchers develop CRISPR-based tests for leukemia
By LabPulse.com staff writers
Researchers at the Dana-Farber Cancer Institute have created CRISPR-based diagnostics for two types of gene fusion-driven leukemia.
October 10, 2024
Blood Test Samples Lab Social
Exact Sciences gets FDA approval for next-gen Cologuard Plus test
By LabPulse.com staff writers
Exact Sciences has received U.S. Food and Drug Administration (FDA) approval for its next-generation Cologuard Plus colorectal cancer (CRC) screening test.
October 7, 2024
Fda Sign Dc Social
Geneoscopy adds N.Y. state lab permit for wider ColoSense testing
By LabPulse.com staff writers
Noninvasive colorectal cancer screening test developer Geneoscopy has received a laboratory permit from the New York State Department of Health.
October 1, 2024
Colorectal Cancer Social (1)
Ibex survey indicates some comfort with AI in cancer diagnostics
By LabPulse.com staff writers
A recent survey reports that more than 50% of U.S. adults have received an incorrect medical test result for themselves or a loved one. Additionally, 60% would trust artificial intelligence (AI) supporting medical diagnoses.
September 25, 2024
Doctor Patient Consult
Scancell, PharmaJet sign agreement for melanoma vaccine delivery system
By LabPulse.com staff writers
Clinical-stage biopharmaceutical company Scancell has signed a strategic partnership agreement with PharmaJet for the supply of PharmaJet's needle-free Stratis delivery system for the delivery of Scancell's advanced melanoma vaccine.
September 18, 2024
Business Agreement Social
AI model shows promise for 'virtual staining' of cancerous tissue
By LabPulse.com staff writers
Researchers have created an artificial intelligence (AI) model that generates images showing virtual colorations of cancerous tissue.
September 12, 2024
Pathology Digital Workstation Microscope Social
A. Menarini, Nucleix sign distribution agreement for bladder cancer test
By LabPulse.com staff writers
A. Menarini Diagnostics and liquid biopsy firm Nucleix have signed a strategic partnership for the exclusive distribution of Nucleix's Bladder EpiCheck test.
September 9, 2024
Bladder Urinary 3 D Social
Hitachi High-Tech, Gencurix forge agreement on cancer diagnostics
By LabPulse.com staff writers
Hitachi High-Tech and oncology molecular diagnostics firm Gencurix have formed a strategic partnership aimed at developing cancer diagnostics and testing services.
August 30, 2024
Hands Shaking2 Social
Upcoming lung cancer molecular testing guidelines address 7 questions
By Liz Carey
Revised guideline addresses next-generation sequencing and expanded biomarker testing.
August 28, 2024
Lung Cancer Hotspot Social
University of Eastern Finland researchers develop algorithm for better breast cancer screening
By LabPulse.com staff writers
Researchers at the University of Eastern Finland have developed an algorithm to improve mammogram density assessment, with the potential to increase screening accuracy.
August 23, 2024
Breast Mammo Social
Alpenglow Biosciences lands $24M for 3D pathology platform
By LabPulse.com staff writers
Company gets boost to commercialize direct-to-digital pathology platform and AI.
August 15, 2024
Money Hundred Bills Social
Page 1 of 98
Next Page